Roth Capital Lowers Earnings Estimates for Aurora Cannabis

Key Points

• Roth Capital has lowered its Q2 2026 earnings estimate for Aurora Cannabis from $0.23 to $0.12 per share, while the current full-year consensus estimate stands at $0.46 per share.
• Aurora Cannabis reported a loss of $0.19 per share for its latest quarter, significantly missing the consensus estimate of $0.18, and posted revenues of $71.98 million which fell short of the expected $96.83 million.
• Following the adjustments in earnings estimates, Wall Street Zen downgraded Aurora's shares from "hold" to "sell," reflecting a cautious outlook on the company's performance.

Aurora Cannabis Inc. (NASDAQ:ACB - Free Report) - Analysts at Roth Capital dropped their Q2 2026 earnings estimates for shares of Aurora Cannabis in a report issued on Wednesday, August 6th. Roth Capital analyst W. Kirk now expects that the company will post earnings per share of $0.12 for the quarter, down from their previous forecast of $0.23. The consensus estimate for Aurora Cannabis' current full-year earnings is $0.46 per share. Roth Capital also issued estimates for Aurora Cannabis' Q3 2026 earnings at $0.59 EPS and Q4 2026 earnings at ($0.09) EPS.

Aurora Cannabis (NASDAQ:ACB - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.37). Aurora Cannabis had a negative net margin of 5.66% and a negative return on equity of 1.49%. The business had revenue of $71.98 million for the quarter, compared to analyst estimates of $96.83 million.

Separately, Wall Street Zen lowered shares of Aurora Cannabis from a "hold" rating to a "sell" rating in a research report on Friday, July 18th.

Aurora Cannabis Price Performance

Shares of Aurora Cannabis stock opened at $4.48 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.51 and a current ratio of 2.97. The firm's 50-day simple moving average is $4.79 and its 200-day simple moving average is $4.80. Aurora Cannabis has a twelve month low of $3.42 and a twelve month high of $7.20. The firm has a market cap of $252.90 million, a P/E ratio of -23.58 and a beta of 1.84.

Hedge Funds Weigh In On Aurora Cannabis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ACB. Two Sigma Advisers LP lifted its position in shares of Aurora Cannabis by 18.7% during the fourth quarter. Two Sigma Advisers LP now owns 62,100 shares of the company's stock worth $264,000 after purchasing an additional 9,793 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Aurora Cannabis in the fourth quarter valued at approximately $67,000. Dimensional Fund Advisors LP boosted its holdings in shares of Aurora Cannabis by 7.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 84,921 shares of the company's stock valued at $361,000 after buying an additional 5,800 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Aurora Cannabis by 8.6% in the fourth quarter. Renaissance Technologies LLC now owns 714,655 shares of the company's stock valued at $3,037,000 after buying an additional 56,400 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new position in Aurora Cannabis during the fourth quarter worth $221,000. 47.63% of the stock is currently owned by institutional investors and hedge funds.

Aurora Cannabis Company Profile

Aurora Cannabis Inc, together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.